WEST PHARMACEUTICAL SERVICES INC 4

President and CEO Michel Lagarde received new stock option grants and restricted stock unit awards in West Pharmaceutical Services, Inc. (WST) on September 8, 2026, materially increasing his equity-based compensation exposure.

On September 8, 2026, Michel Lagarde, President and CEO of West Pharmaceutical Services, Inc., received multiple equity-based compensation awards, including three stock option grants with an exercise price of $337.75 per share for 13,879, 11,081, and 12,088 shares respectively, as well as three restricted stock unit (RSU) awards for 6,200, 4,950, and 3,600 shares of common stock. The RSUs represent contingent rights to receive an equivalent number of WST common shares, with one award vesting in four equal annual installments beginning September 8, 2027, and another award cliff-vesting on September 8, 2031, indicating long-term incentive alignment. No shares were purchased or sold for cash in the market; these are grants/awards that increase the CEO’s potential and actual ownership stake. Using the current stock price of approximately $343.76, the aggregate intrinsic value of the RSU awards is about $5.14 million, and if the options were in-the-money at the current price, their total notional economic exposure would exceed $11 million, although that value depends on future stock performance and vesting. Post-award, Lagarde’s direct holdings are increased by the full RSU share counts, with the options representing additional contingent rights to acquire common stock through 2036.

Filing Facts

CIK

105770

Ticker

WST

Form

4

Source Type

fda

Accession

0001518973-26-000007

Alert Tier

7